Serge Muyldermans

发表

A guide to: generation and design of nanobodies

Serge Muyldermans, S. Muyldermans, 2020, The FEBS journal.

Nanobodies as novel agents for cancer therapy

Serge Muyldermans, Patrick De Baetselier, Hilde Revets, 2005, Expert opinion on biological therapy.

A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme

Christopher M. Dobson, Mireille Dumoulin, Lode Wyns, 2003, Nature.

Minimum information about a protein affinity reagent (MIAPAR)

Henning Hermjakob, David Juncker, David E. Gloriam, 2010, Nature Biotechnology.

Potent enzyme inhibitors derived from dromedary heavy‐chain antibodies

Lode Wyns, Serge Muyldermans, L. Wyns, 1998, The EMBO journal.

Nanobodies as Probes for Protein Dynamics in Vitro and in Cells*

Serge Muyldermans, S. Muyldermans, Svetlana Lutsenko, 2015, The Journal of Biological Chemistry.

Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme

Lode Wyns, Serge Muyldermans, L. Wyns, 1996, Nature Structural Biology.

Efficient cancer therapy with a nanobody-based conjugate.

Serge Muyldermans, Natalija Backmann, Patrick De Baetselier, 2004, Cancer research.

Preclinical screening of anti‐HER2 nanobodies for molecular imaging of breast cancer

Nick Devoogdt, Tony Lahoutte, Serge Muyldermans, 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Nanobodies: natural single-domain antibodies.

Serge Muyldermans, S. Muyldermans, 2013, Annual review of biochemistry.

A synthetic camel anti-lysozyme peptide antibody (peptibody) with flexible loop structure identified by high-resolution affinity mass spectrometry.

Michael Przybylski, Serge Muyldermans, S. Muyldermans, 2006, Chemistry.

Distinct antibody species: structural differences creating therapeutic opportunities.

Serge Muyldermans, S. Muyldermans, Vaughn V. Smider, 2016, Current opinion in immunology.

Crystal Structure of the Intrinsically Flexible Addiction Antidote MazE*

Lode Wyns, Remy Loris, Serge Muyldermans, 2003, Journal of Biological Chemistry.

Single Domain Antibodies Derived from Dromedary Lymph Node and Peripheral Blood Lymphocytes Sensing Conformational Variants of Prostate-specific Antigen*

Serge Muyldermans, Dirk Saerens, S. Muyldermans, 2004, Journal of Biological Chemistry.

A Versatile Nanotrap for Biochemical and Functional Studies with Fluorescent Fusion Proteins*S

M. Cristina Cardoso, Heinrich Leonhardt, Serge Muyldermans, 2008, Molecular & Cellular Proteomics.

A Case Of Convergence: Why Did a Simple Alternative to Canonical Antibodies Arise in Sharks and Camels?

Nick Deschacht, Serge Muyldermans, S. Muyldermans, 2011, PLoS biology.

Position and orientation of the globular domain of linker histone H5 on the nucleosome

V. Ramakrishnan, Andrew Travers, Serge Muyldermans, 1998, Nature.

Efficient tumor targeting by single‐domain antibody fragments of camels

Serge Muyldermans, Patrick De Baetselier, Hilde Revets, 2002, International journal of cancer.

Specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy.

Liesbet Lagae, Gustaaf Borghs, Nick Devoogdt, 2011, ACS nano.

Kinetic and Affinity Predictions of a Protein-Protein Interaction Using Multivariate Experimental Design*

Serge Muyldermans, Karl Andersson, K. Decanniere, 2002, The Journal of Biological Chemistry.

Three Camelid VHH Domains in Complex with Porcine Pancreatic α-Amylase

Lode Wyns, Serge Muyldermans, Christian Cambillau, 2002, The Journal of Biological Chemistry.

Generation of a functional monomolecular protein lattice consisting of an s-layer fusion protein comprising the variable domain of a camel heavy chain antibody.

Serge Muyldermans, Margit Sára, Uwe B. Sleytr, 2003 .

Heating as a rapid purification method for recovering correctly-folded thermotolerant VH and VHH domains

Ario de Marco, Serge Muyldermans, S. Muyldermans, 2007, BMC biotechnology.

Targeting and tracing antigens in live cells with fluorescent nanobodies

Heinrich Leonhardt, Lothar Schermelleh, Serge Muyldermans, 2006, Nature Methods.

Synthesis, Preclinical Validation, Dosimetry, and Toxicity of 68Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer

Marleen Keyaerts, Nick Devoogdt, Tony Lahoutte, 2013, The Journal of Nuclear Medicine.

Exploiting sequence and stability information for directing nanobody stability engineering

Tilman Flock, Moritz Zaiss, Jörg D. Hoheisel, 2017, Biochimica et biophysica acta. General subjects.

Reduced global cooperativity is a common feature underlying the amyloidogenicity of pathogenic lysozyme mutations.

Mireille Dumoulin, Lode Wyns, Christopher M Dobson, 2005, Journal of molecular biology.

Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle

Marleen Keyaerts, Nick Devoogdt, Tony Lahoutte, 2016, Expert opinion on biological therapy.

Prostate-specific antigen immunosensing based on mixed self-assembled monolayers, camel antibodies and colloidal gold enhanced sandwich assays.

Jean-Michel Friedt, Laurent Francis, Andrew Campitelli, 2005, Biosensors & bioelectronics.

Nanobodies and recombinant binders in cell biology

M. Cristina Cardoso, Heinrich Leonhardt, Serge Muyldermans, 2015, The Journal of cell biology.